OUR SERVICES
We provide consulting and research services in IgA Nephropathy in the following areas:
Consultation regarding novel therapeutics for IgA nephropathy
Testing for disease-specific biomarkers of IgA nephropathy including:
The combination of these two assays have been demonstrated to disease-specific markers for IgA nephropathy. Currently the use of these assays is for research purposes only.
Scientific Literature:
AUTOANTIBODY ASSAY
Assay for autoantibody specific for galactose-deficient IgA1
(anti-Gd-IgA1 autoantibody)
This assay is based on the original discovery in Dr. Novak's group at UAB of the presence of autoantibodies in the serum of patients with IgA nephropathy. These autoantibodies are specific for galactose-deficient IgA1. The assay is an ELISA-based assay that has been extensively used in Dr. Novak's research laboratory and tested with several different patient cohorts.
Scientific Literature about our assay:
The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol. 22, 1795-1803, 2011.
IgA nephropathy. New England Journal of Medecine. 368, 2402-2414, 2013.
GALACTOSE-DEFICIENT IGA1 ASSAY
ELISA for galactose-deficient IgA1
We also provide an assay that measures the extent of IgA1 galactose deficiency. This assay has been used as a means to determine serum levels of galactose-deficient IgA1. The use of this assay established that serum levels of galactose-deficient IgA1 are elevated in patients with IgAN and predict disease progression.
Scientific Literature about this assay:
Statement Regarding Financial Conflict of Interest for Research Funded Under PHS Grants:
Reliant Glycosciences, LLC takes seriously each potential Conflict of Interest that could affect the integrity of any Public Health Service (PHS)-funded research that is performed by its employees and sub-recipients. As a result, and in compliance with federal law and regulations, Reliant Investigators shall not participate in any PHS-funded Research if he or she has a Financial Conflict of Interest (FCOI) that could influence the design, conduct, or reporting of such research activity. Reliant will take immediate action under this policy to manage, reduce, or eliminate any such Conflict of Interest. As set forth herein, all PHS-funded Research undertaken at Reliant shall be conducted in full compliance with this policy and with all applicable federal and state laws pertaining to financial conflicts of interest, including, without limitation, Title 42 Code of Federal Regulations (CFR) Part 50 Subpart F for grants and cooperative agreements and Title 45 CFR Part 94 for Research contracts (collectively, FCOI Regulations). Investigators failing to comply with all FCOI Regulations shall be subject to sanctions, up to and including termination of employment.